Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)

Inclusion criteria

Subjects must:

• have been diagnosed with acute rhinosinusitis
• have had signs and symptoms of rhinosinusitis for at least 7 but not more than 28 days prior to Baseline
• have had a major symptom score >=5 and <=12 at the Screening and Baseline, and no more than 3 of the 5 major individual symptoms were to be rated as "severe"
• be >=12 years old
• be in good health overall and normal laboratory tests
• not be pregnant, intending to become pregnant or intending to impregnate.

Exclusion criteria

Subjects who:

• have a history of chronic rhinosinusitis or who had undergone sinus or nasal surgery for chronic rhinosinusitis in the 6 months prior to Screening
• have fever >=101°F and/or persistent severe unilateral facial pain/tooth pain; and/or orbital or peri-orbital facial swelling; and/or dental involvement; and/or worsening symptoms after initial improvement
• have a history of symptomatic seasonal allergic rhinitis who were exposed to allergenic pollens
• have asthma with FEV1<65% of predicted volume in the past 3 months or who have had an exacerbation within the past 30 days
• have nasal polyps, Kartagener's syndrome, and otitis or atrophic rhinitis
• have certain comorbid conditions or contraindications to certain drug therapies